Labtician OphthalmicsLabtician Ophthalmics

Menu
  • International
  • About Us
  • For Patients
  • Buy Online
  • French
  • Surgical Products
  • Therapeutic Products
  • Product Search
  • Resources
  • Contact Us
  • Surgical Products
  • Therapeutic Products
  • Product Search
  • Resources
  • International
  • Contact Us
  • About Us
  • For Patients
  • Buy Online
  • English

Home / Archives for Lisa Dockray

Press Release: LABTICIAN THÉA ANNOUNCES SUCCESSFUL COMPLETION OF JOINT VENTURE RESULTING IN A STRONGER LABTICIAN OPHTHALMICS, AND LAUNCH OF THÉA PHARMA CANADA

May 10, 2022 by Lisa Dockray

Canadian Eye Care Professionals and their Patients to Benefit from Innovative New Services, Increased Support, and Best-in-Class Products

Oakville, ON: May 10th 2022 – As two world-class family companies with a passion for eye care, Laboratoires Théa and Labtician Ophthalmics recognized an opportunity to work together to bring innovative new products to Canadian patients. In 2018, this shared vision resulted in the formation of Labtician Théa, an ambitious Joint Venture with a 5-year term.

By focusing on supporting Canadian Eye Care professionals provide optimal care to their patients, the Labtician Théa Joint Venture has achieved its goals of creating a strong presence in the Canadian marketplace and offering Canadian Eye Care Professionals the most comprehensive suite of products and services available in the industry. From diagnostics and surgical equipment that provide solutions across Cornea, Glaucoma and Retinal Diseases, to cutting-edge preservative-free treatments for the management of Glaucoma, Dry Eye Disease and Lid Hygiene, Labtician Théa has brought innovation to practice for clinicians and their patients.

With the successful completion of the agreed-upon 5-year term, as of January 1, 2023, the Joint Venture will terminate, resulting in a stronger Labtician Ophthalmics with a new Therapeutics Division to complement its existing Surgical Division, and the launch of Théa Pharma Canada Inc., an affiliate of Laboratoires Théa, based in the Greater Toronto Area. As two separate entities, Labtician Ophthalmics and Théa Pharma Canada will be better positioned to service and support the Canadian Eye Care community for many years to come.

“Our partnership with Labtician Ophthalmics has allowed us to get to know the Canadian Eye Care professionals and understand their needs and that of their patients. It was a great way to introduce them to Théa and bring innovative best-in-class products to market that are supported by strong clinical evidence,” says Fiona McCloskey, Managing Director of Labtician Théa and Théa Pharma Canada. “Since the start of the Joint Venture with Labtician Ophthalmics, Eye Care Professionals and patients have come to know and trust Théa products, allowing us to build a reputation and truly make a difference in patient lives every day. With the launch of Théa Pharma Canada in 2023, our goal is to continue to provide ECPs and patients with new innovative treatments and solutions for a wide range of ocular diseases including Dry Eye, Glaucoma, Allergy and more over the years to come. We are thankful for our partnership with Labtician Ophthalmics and excited for this new chapter in our journey as Théa Pharma Canada.”

This unique Joint Venture has also been a success for the team at Labtician Ophthalmics.

“Working with the world-class team and products at Théa allowed us to demonstrate our unique ability to platform other companies in the Canadian marketplace and showcase our skill of developing unprecedented business models and executing against them,” says Polydor Strouthos, President of Labtician Ophthalmics. “We built on our expertise in regulatory, cross-functional marketing, and customer expansion, and increased our capacity to launch products and entities. We bring innovation to practice and will provide our valued customers with more best-in-class products, services, and innovative solutions due to a stronger Labtician Ophthalmics with a new Therapeutics Division to complement our existing Surgical Division.
When mutually beneficial opportunities arise, Théa Pharma Canada Inc. and Labtician Ophthalmics Inc. will leverage their strong relationship and shared family values as Partners of Choice, and look forward to robust, sustained growth for both companies in the years to come.

For More Information:
Fiona McCloskey, Managing Director
Labtician Théa and Théa Pharma Canada
Tel: 416-669-0585
Fiona.McCloskey@labticianthea.com

Polydor Strouthos, President
Labtician Ophthalmics, Inc.
Tel: 905-829-0055 ext. 227
pstrouthos@labtician.com

ABOUT LABTICIAN OPHTHALMICS, INC.

Labtician Ophthalmics, Inc. is a solutions-focused provider of specialty medical devices and pharmaceutical products to the Canadian Eyecare community. With 60 years of history in Canada, Labtician Ophthalmics Inc. continues its tradition of bringing innovation to practice through the commercialization of exclusive and innovative medical devices for use in surgery. Now as a stronger Labtician Ophthalmics with a new Therapeutics Division to complement the existing Surgical Division we provide our valued customers with even more best-in-class products, services, and innovative solutions including our expertise in launching products and entities into the Canadian marketplace.

ABOUT THÉA PHARMA CANADA INC.

Théa Pharma Canada, Inc. is an affiliate of Théa, the leading independent Eye Care group in Europe specializing in the research, development, and commercialization of products exclusive to Eye Care. With over 150 years of history, the family owned and run company is the pioneer and leader in the development of preservative-free treatments. Today, it constitutes a network of more than 1500 employees worldwide, and its products are available in more than 75 countries. With the launch of Théa Pharma Canada in 2023, our goal is to continue to provide ECPs and patients with innovative treatments and cutting-edge solutions for a wide range of ocular diseases including Dry Eye, Glaucoma, Allergy and more over the years to come.

Filed Under: Press Release

Press Release: CAN Health Network and Quebec-Based DIAGNOS Announce Partnership

March 16, 2022 by Lisa Dockray

     
 

CAN Health Network and Quebec-Based DIAGNOS Announce Life-Changing Diabetic Retinopathy Screening Program Partnership

Innovative diabetic retina screening service resulting in earlier intervention, better care, and savings to the Canadian healthcare system.

March 15, 2022 (Montréal, Québec) – The Coordinated Accessible National (CAN) Health Network is excited to announce that leading vision care company, DIAGNOS, is the first Quebec-based organization to join the Network. Through their strategic partner, Labtician Ophthalmics Inc, a Toronto-based company with Eyecare Specialist customers across Canada, DIAGNOS’ CARA solution will help health care professionals in their day-to-day screening of diabetic patients by allowing them to monitor ocular health, ultimately helping to prevent vision loss in their patients.

Diabetic Retinopathy is the leading cause of blindness, and early detection has been identified as the best preventative measure and solution. Patients who require these critical screenings often come up against barriers resulting in non-compliance, high costs, or a missed diagnosis, leading to potentially life-altering vision loss. In particular, DIAGNOS’ solution will help professionals identify patients who are overdue for a screening, ensuring Diabetic Retinopathy is caught early. This low-cost, non-invasive state-of-the-art technology involves the use of a simple rear eye camera image, which quickly and effectively screens patients. Assessment results are then returned within a few minutes; saving both time and health care costs.

“DIAGNOS, a publicly traded company on the TSX Venture Exchange, is pleased to be part of the CAN-Health Network,” said André Larente, CEO, DIAGNOS. “Our solution for screening diabetic patients uses Artificial Intelligence. The CARA application is approved by Health Canada and is in use today in hospitals and primary care clinics. This new local screening program will give accessibility to all patients in Canada to a fast and low priced medical test.”

Funded by Government of Canada, the CAN Health Network works with health care providers to identify their biggest challenges, and matches them with Canadian-made technology solutions. This Integrated Market model allows Canadian innovators to gain access to the healthcare market, and rapidly validate and scale their solution across the country, and internationally.

“The CAN Health Network has been focused on accessing the Quebec marketplace to ensure a truly national scope and economic prosperity for all of Canada. Adding DIAGNOS and Labtician to the Network is another great step in ensuring all Canadians have access to the best home-grown innovative health care technologies,” said Dante Morra, Chair, CAN Health Network.

“We are pleased to be working with CAN Health Network and DIAGNOS, a Canadian company based in Quebec, in addressing growing needs in the monitoring of diabetic patients,” explains Labtician President, Polydor Strouthos. “For over 60 years, we’ve been introducing innovative eye care products, solutions, and resources for eyecare professionals and their patients in the Canadian marketplace. Through our extensive network, we commercialize our high-quality value add eyecare products as well as those of our forward-thinking partner companies in Canada and worldwide. We help companies through the complexities and nuances of Canadian and international markets, from prelaunch assistance and obtaining regulatory approval, to securing commercialization, and distribution channels.”

ASSOCIATED LINKS

  • Government of Canada provides more support to CAN Health Network
  • DIAGNOS
  • Labtician Ophthalmics, Inc.

ABOUT DIAGNOS

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based of its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia). DIAGNOS works with AI Distributor, Labtician Ophthalmics (Labtician).

ABOUT CAN HEALTH

The CAN Health Network is a Canada-first approach to technology adoption. It helps break down barriers to scaling in the health care system and provides an environment for companies to scale to their full potential. Currently operating in Ontario, Western and Atlantic Canada, the CAN Health Network will soon be expanding into Quebec and the North. The Network has received a total of $12.45 million in funding from the Government of Canada to build a national platform that harnesses the purchasing power of health care organizations. To learn more about the CAN Health Network, visit canhealthnetwork.ca.

For more information:

Mr. Polydor Strouthos, President
Labtician Ophthalmics, Inc.
Tel: 905-829-0055 ext. 227
pstrouthos@labtician.com

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

Natasha Zelinski, Communications Coordinator
CAN Health Network
natasha.zelinski@thp.ca

Filed Under: Press Release

Literature Review: Use of Plasma Rich in Growth Factors (PRGF) in Ophthalmology

February 9, 2022 by Lisa Dockray

 

Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus.

Anitua E, de la Sen-Corcuera B, Orive G, Sánchez-Ávila RM, Heredia P, Muruzabal F, Merayo-Lloves J. Expert Opin Biol Ther. 2021 Jul 19:1-15. doi: 10.1080/14712598.2021.1945030. Epub ahead of print. PMID: 34275392.

Introduction: The use of blood derivatives and especially Plasma rich in growth factors (PRGF), for regenerative purposes has been a common trend along the last decades in the field of oral surgery, dermatology, orthopedics, and more recently in ophthalmology.

Areas covered: PRGF is a type of platelet-rich plasma that is being explored for the treatment of ocular injuries. The present review article highlights 50 ophthalmology-related publications about the application of PRGF in the treatment of acute and chronic pathologies in ophthalmology as well as most relevant challenges and future prospects.

Expert opinion: PRGF technology provides a wide range of formulations that can be used therapeutically in many different acute and chronic ocular pathologies. In addition to eye drops enriched with autologous growth factors, PRGF enables the preparation of both immunologically safe and fibrin-based formulations. Recent advances in the field have promoted PRGF storage for 12 months under freezing conditions, its daily use for 7 days at room temperature and the freeze-dried formulation. The thermally treated immune-safe formulation has shown promising clinical results for the treatment of several diseases such as Sjögren syndrome, graft versus host disease or cicatrizing conjunctivitis. In addition, several fibrin formulations have been pre-clinically evaluated and clinically incorporated as an adjuvant to ocular surface or glaucoma surgeries, dermal fat graft procedures, limbal stem cell expansion and retinal surgeries. The present review explores the latest scientific and clinical data, current challenges, and main prospects of this technology for the treatment of several ocular injuries.


 

*PRGF compared with Autologous Serum (Pre-Clinical Evidence):

Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts.

Anitua E, de la Fuente M, Muruzabal F, Riestra A, Merayo-Lloves J, Orive G. Exp Eye Res. 2015 Jun;135:118-26. doi: 10.1016/j.exer.2015.02.016. Epub 2015 Feb 21. PMID: 25708868.

Conclusion/Findings: “…significant higher levels of all growth factors analyzed in PRGF eye drops compared to AS. Moreover, PRGF eye drops enhanced significantly the biological outcomes of both HK and HConF, and reduced TGF-b1-induced myofibroblast differentiation in contrast to autologous serum eye drops (AS). In summary, these results suggest that PRGF exerts enhanced biological outcomes than AS. PRGF may improve the treatment of ocular surface wound healing minimizing the scar formation compared to AS. Results obtained herein suggest that PRGF protects and reverses the myofibroblast phenotype while promotes cell proliferation and migration.”


 

*PRGF compared with Autologous Serum and PRP (Pre-Clinical Evidence):

Corneal wound healing promoted by 3 blood derivatives: an in vitro and in vivo comparative study.

Freire V, Andollo N, Etxebarria J, Hernáez-Moya R, Durán JA, Morales MC. Cornea. 2014 Jun;33(6):614-20. doi: 10.1097/ICO.0000000000000109. PMID: 24727633.

Conclusion/Findings: In vitro data show statistically significant differences in the healing process with all the derivatives compared with the control, but 2 of them (AS and s-PRGF) induced markedly faster wound healing. In contrast, although the mean time required to complete in vivo reepithelization was similar to that of AS and s-PRGF treatment, only wounds treated with s-PRGF were significantly smaller in size from 2.5 days onward with respect to the control treatment. …the corneal wound-healing progresses differently with each derivative, being faster in vitro under AS and s-PRGF treatment and producing in vivo the greatest decrease in wound size under s-PRGF treatment.”


 

*Endoret PRGF: Safety and Efficacy in Ocular Surface Disorders (Clinical Evidence)

Safety and Efficacy of Autologous Plasma Rich in Growth Factors Eye Drops for the Treatment of Evaporative Dry Eye.

Merayo-Lloves J, Sanchez-Avila RM, Riestra AC, Anitua E, Begoña L, Orive G, Fernandez-Vega L. Ophthalmic Res. 2016 Jul;56(2):68-73. doi: 10.1159/000444496. Epub 2016 May 28. PMID: 27229893.

Description: This retrospective study included patients with EDE treated between January 2011 and December 2013. Outcome measures including signs and symptoms of the disease were evaluated before and after treatment. The influence of some of the patient’s clinical variables on results was assessed. Safety assessment was also performed.

Findings & Conclusions: Eighty-three patients with a total of 156 eyes were evaluated. Statistically significant reductions in the Ocular Surface Disease Index (38.2%), best-corrected visual acuity (27.4%), Visual Analogue Scale scores for frequency (32%) and severity (34%), and a significant improvement in the Schirmer test scores (177.5%) were observed (p < 0.05). The results were stratified according to the identified potential effect modifiers. Only four adverse events were reported. All of them were mild and resolved within a few days.

Results suggest that PRGF eye drops could be a safe and effective treatment in reducing EDE signs and symptoms.


 

*Endoret PRGF: Safety and Efficacy in Ocular Surface Disorders (Clinical Evidence)

Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops.

Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, Fernandez-Vega Cueto L, Anitua E, Begoña L, Muruzabal F, Orive G. Int Ophthalmol. 2018 Jun;38(3):1193-1204. doi: 10.1007/s10792-017-0582-7. Epub 2017 Jun 15. PMID: 28620707.

Description: This retrospective study included patients with stages 2-3 of NK treated with PRGF eye-drops. Primary endpoint was the resolution time of corneal ulcer defect. Outcome measures including percentage of ulcer closure at 4 weeks, Ocular Surface Disease Index (OSDI), Best-Corrected Visual Acuity (BCVA) and Visual Analogue Scale (VAS) were also evaluated before and after treatment with PRGF. The influence of some patients’ clinical variables on results was assessed. Safety assessment was also performed reporting all adverse events.

Findings & Conclusions: Thirty-eight treated eyes in a total of thirty-one patients were evaluated, of which five cases had no prior response to autologous serum treatment. Most cases (97.4%) achieved the complete resolution of corneal defect/ulcer. Mean resolution time was 11.4 weeks (SD = 13.7). A statistical significant (p < 0.05) reduction in OSDI (60.9%), VAS frequency (59.9%), VAS severity (57.0%) and improvement in BCVA (52.8%) was observed. The results were stratified according to the pathology stage and to the identified potential effect modifiers variables. Only one adverse event was reported in one patient (2.6%).

PRGF eye-drops could be a safe and effective therapeutic option for patients with stages 2-3 of NK, showing high rates of corneal defect/ulcer resolution in short times, either in reducing signs and symptoms of NK, and therefore preventing the progression of NK to greater ocular complications.

Filed Under: Clinicals Tagged With: Plasma rich in growth factors, PRGF, Endoret

Taking Ocular Surface Regeneration to the Next Level

February 9, 2022 by Lisa Dockray

Clinical Application of Endoret® (Plasma Rich in Growth Factors) in Refractory Ocular Surface Disease Patients. PRGF is a personalised technology that has revolutionised the field of regenerative medicine. Its application over the last decade has extended to many fields of medicine, from oral and maxillofacial surgery to dermatology, cosmetics, orthopaedic surgery and sports medicine, and more recently to ophthalmology.

During this webinar Dr. Mather, Dr. Slomovic and Dr. Rocha will each share their personal clinical experience with Endoret showcasing its application in a variety of refractory OSD conditions.

Dr Guillermo Rocha
Ocular Microsurgery & Laser Centre
Anterior Segment and Cornea
Dr Allan Slomovic
Toronto Western Hospital
Cornea/External Disease
Dr Rookaya Mather
Ivey Eye Institute
Cornea/External Disease

Click here for the literature review on PRGF use in Ophthalmology

Filed Under: Webinars

Excisional Goniotomy for the Cataract Practice

February 2, 2022 by Lisa Dockray

Dr. Blake Williamson illustrates the use of excisional goniotomy with the Kahook Dual Blade (KDB) to treat multiple glaucoma patient types in a comprehensive cataract practice. In addition, Dr. Gavin Docherty will share his experience using the KDB in his comprehensive practice.

Objectives of the webinar:

  • Introduction to Excisional Goniotomy with the Kahook Dual Blade
  • Patient selection for a comprehensive cataract practice
  • Pre-op, post-op patient management and current data

Dr Blake Williamson
Williamson Eye Center
Dr Gavin Docherty
Kelowna General Hospital

Click here for more information on Kahook Dual Blade

Filed Under: Webinars

Ahmed ClearPath®
Pearls for success with the latest Glaucoma Drainage Device

October 28, 2021 by Lisa Dockray


Dr. Leon Herndon, Dr. Paul Harasymowycz and Dr. Patrick Gooi share their experience with the Ahmed ClearPath®, the latest innovation in Glaucoma Drainage Devices. The webinar covers clinical cases and videos to demonstrate the use of ClearPath® 250 and 350 in treating refractory glaucoma.

Objectives of the webinar:

  • Design intent and introduction to the ClearPath®
  • Clinical data
  • Small incision technique with CP250
  • Novel device to simplify ligation and fenestration of valveless GDDs

Click here for more information on ClearPath®

Filed Under: Webinars

The BioDOptix dehydrated amnion graft: indications and pearls for success

Dr Clara Chan & Dr Michael Mimouni
Recorded Webinar

May 19, 2021 by Lisa Dockray

Dr Clara Chan and Dr Michael Mimouni share their experience with BioDOptix, the first and only Dehydrated Amnion Graft in Canada. This webinar covers clinical cases and videos to demonstrate the use of BioDOptix in treating a number of corneal and dry eye conditions.

Objectives of the webinar:

  • Indications for using amniotic membrane grafts
  • Techniques of applying dehydrated amniotic membrane to the ocular surface
  • Pearls for troubleshooting and how to ensure a happy patient

Dr Clara Chan
University of Toronto
Dr Michael Mimouni
University of Toronto

Click here for more information on BioDOptix.

Filed Under: Webinars

Exclusive Strategic Partner Agreement between Diagnos and Labtician Ophthalmics

March 3, 2021 by Lisa Dockray

DIAGNOS Announces its Exclusive Strategic Partnership Agreement with Labtician Ophthalmics, a Leader in Canadian and International Eyecare Markets to Address Growing Needs in the Monitoring of Diabetic and Hypertensive Patients

Brossard, Quebec, Canada – February 24, 2021 – Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces its exclusive strategic partnership agreement with Labtician Ophthalmics (“Labtician”), a Toronto-based company with customers across Canada who will introduce and commercialize DIAGNOS AI platform to monitor ocular health and improve patient care in diabetic patients. An initial agreement with Labtician was announced on June 3rd, 2020.

In an effort to increase its footprint and accelerate its growth, DIAGNOS has decided to work with organizations that are active in similar markets. The formalization of this strategic partnership with Labtician will have the net effect of allowing access to new customers across Canada. DIAGNOS’ CARA solution allows close monitoring of the effects of medications used in retinal microcirculation to help professionals in their day-to-day screening of their patients.

“We are pleased to be working with DIAGNOS in addressing growing needs in the monitoring of diabetic and hypertensive patients. For over 60 years, we’ve been world leaders in innovative eye care products, solutions, and resources for eyecare professionals and their patients. Through our extensive network, we commercialize our high-quality eyecare products as well as those of our forward-thinking partner companies in Canada and worldwide. We help companies through the complexities and nuances of Canadian and international markets, from prelaunch assistance and obtaining regulatory approval, to securing commercialization, and distribution channels,” explains Labtician President, Polydor Strouthos.

“I am pleased to be working with the team at Labtician. Labtician brings a high-level of expertise in the Canadian healthcare marketplace. Our growth strategy is to create partnerships in select countries thereby leveraging local relationships to accelerate the adoption of DIAGNOS’ CARA AI Platform. Labtician is the ideal partner due to their long history of working closely with Canadian Optometric and Ophthalmology professionals dedicated to treating the effects of diabetes on the eyes and preventing vision loss,” explains DIAGNOS CEO, André Larente.

Labtician worked with Prism Eye Institute, a CAN Health Network partner, to gain insights in how to best utilize this revolutionary screening technology in the Canadian market. With these insights, Labtician was able to find ways to bring this technology to Canadians using existing care models. The CAN Health Network is focused on building an integrated market and supporting Canadian companies scale.

“More retina screening means earlier intervention, better care, and a massive savings to the system,” said Dr. Ike Ahmed, world renowned Ophthalmologist and Medical Director at Prism Eye Institute, who has led the efforts as part of his commitment to the CAN Health Network. “We are strong supporters of the CAN Health Network and helping world-class Canadian health tech companies succeed. By supporting Canadian companies, our patient’s community and economy all benefit.”

About Labtician
With 60 years of history in Canada, Labtician has evolved from a manufacturer of quality ophthalmic products for the global market to a specialized commercialization partner for the Canadian ophthalmic market. In their capacity as a commercialization partner, they offer the “complete Canadian solution.” Labtician is actively involved in the entire commercialization process from pre-launch, to launch and post-launch. This involves regulatory, market access, importation and distribution as well as sales and marketing activities. Internationally, they offer commercialization expertise through global partners.

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based of its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.diagnos.ca and www.sedar.com.

Please send any questions to info@labtician.com

This press release contains forward-looking information. We cannot guarantee that the forward-looking information mentioned will prove to be accurate, as there may be a significant discrepancy between actual results or future events and those mentioned in this statement. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly covered by this caution.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Filed Under: Press Release

Glaucoma Drainage Devices and the ClearPath to Success Webinar

November 3, 2020 by Lisa Dockray

This webinar is an interactive panel discussion focusing on glaucoma drainage device data, best practices and experiences.

Key topics discussed:

  • Patient Selection for GDDs
  • Novel Surgical Techniques
  • Post-Op Management
  • Current Data
  • Initial Experience with Ahmed ClearPathTM
Thomas Samuelson, MD
Arsham Sheybani, MD
Inder Paul Singh, MD
Founding Partner & Attending Surgeon
Minnesota Eye Consultants
Assistant Professor of Ophthalmology
& Visual Sciences
Washington University School of Medicine
President
The Eye Centers of Racine & Kenosha

Filed Under: Webinars

Glaucoma Drainage Device Webinar

July 17, 2020 by Lisa Dockray

This webinar is a paneled discussion focusing on glaucoma drainage device data, best practices and experiences.

Key topics discussed:

  • Overview of Glaucoma Drainage Devices – Steven Gedde, MD
  • Valved vs Non-Valved Glaucoma Drainage Devices – Summary of ABC & AVB Trials – Donald Budenz, MD, MPH
  • Basic Principles of Glaucoma Drainage Device Surgery – Luis Vazquez, MD, PhD
  • Initial Experience with ClearPathTM, the Newest Valveless Glaucoma Drainage Device – Davinder Grover, MD, MPH
Steven Gedde, MD
Donald Budenz, MD, MPH
Luis Vazquez, MD, PhD
Davinder Grover, MD, MPH
Bascom Palmer Eye Institute
Professor of Ophthalmology
John G Clarkson Chair in Ophthalmology
Vice-Chair of Education & Residency Program Director
UNC Ophthalmology
Kittner Family Distinguished Professor Chair
Chair, Department of Ophthalmology
Bascom Palmer Eye Institute
Assistant Professor of Clinical Ophthalmology
Glaucoma Associates of Texas

Filed Under: Webinars

Next Page »
  • Home
  • Surgical Products
  • Therapeutic Products
  • Product Search
  • Resources
  • International
  • Contact Us

GET THE LATEST UPDATES

Looking to stay on the leading edge of ophthalmic trends and practices? Sign-up today to receive helpful resources, updates, and product specials.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply
footer logo
© 2022 Labtician Ophthalmics, Inc. All rights reserved.
  • Terms of Service
  • Labtician Ophthalmics, Inc. Privacy Policy
  • Labtician Ophthalmics, Inc. Disclaimer
  • Labtician Ophthalmics Customer Service Policy
Website design and development by 1dea Design + Media Inc.